Lung cancer remains one of the most common and deadly cancers worldwide. Smoking is responsible for approximately half of all lung cancer cases, making it the single most preventable cause of this disease. For individuals who have smoked for years, quitting can be difficult, and many turn to alternatives like electronic cigarettes (e-cigarettes) as a …
Lung Cancer
Embark on a focused exploration of Lung Cancer within our dedicated subcategory. Tailored to address the nuances of this prevalent and impactful condition, our ‘Lung Cancer’ section provides a comprehensive understanding. Navigate through informative articles, expert perspectives, and the latest advancements in research and treatment options specific to lung cancer. Whether you’re seeking insights on early detection, treatment modalities, or strategies for managing the unique challenges associated with lung cancer, our subcategory serves as a reliable and informative resource. Empowering individuals, caregivers, and healthcare professionals, we aim to foster awareness and understanding to navigate the complexities of lung cancer. Join us on a journey toward informed decision-making and proactive lung health within this specialized arena of oncology.
A new article published in the NEJM showing impressive efficacy in NSCLC, here’s the summary below. The landscape of non-small cell lung cancer (NSCLC) treatment continues to evolve, particularly for patients with EGFR mutations. Historically, EGFR tyrosine kinase inhibitors (TKIs) like osimertinib have been the first line of defense, providing improved progression-free survival for patients. …
Small-cell lung cancer (SCLC) is a notoriously aggressive form of lung cancer, making up about 15% of all lung cancer cases. While treatments have made strides in extensive-stage SCLC, limited-stage SCLC has seen few advancements in decades—until now. A new clinical trial published in the New England Journal of Medicine has revealed promising results with the use …
EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) EGFR (epidermal growth factor receptor) is a protein located on the surface of cells that regulates their growth and division. Mutations in the EGFR gene can lead to uncontrolled cell growth and are commonly found in various cancers, including non-small cell lung cancer (NSCLC). In patients with unresectable stage …
New exciting data published in the NEJM demonstrating improved for a specific subset of lung cancer patients but also demonstrating the power of targeted therapies when we can identify a driver mutation that is sensitive or “actionable” with a treatment to shut down its specific function. Exciting! Non-Small Cell Lung Cancer (NSCLC) represents a significant …
I’m currently on the inpatient medical oncology service. As an attending, we each take turns each month taking all oncology consults for the downtown hospital center. There was an interesting patient our team saw this past week who presented with a new diagnosis of Stage IV NSCLC and SVC syndrome. A 52-year-old woman who, amidst …
New data published in NEJM may new treatment options for patients dealing with metastatic small cell carcinoma! Small-cell lung cancer (SCLC) stands as one of the most aggressive forms of cancer, often leaving patients and their families grappling with limited treatment options and a prognosis that can seem disheartening. But amidst these challenges, there emerges …
I am really excited about this new protocol specifically for patients with MAGE4+ HLA restricted SPEAR TILs for Metastatic Melanoma, Non-small Cell Lung Cancer, Head Neck cancer, Ovarian, Endometrial, and Urothelial cancers. The Gastric and Esophageal Cancer cohorts are closed. The social media material seen here was approved both the sponsor and IRB. Please contact …